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Abstract Dynactin is a complex motor protein involved in
the retrograde axonal transport disturbances of which may
lead to amyotrophic lateral sclerosis (ALS). Mice with
hSOD1G93A mutation develop ALS-like symptoms and are
used as a model for the disease studies. Similar symptoms
demonstrate Cra1 mice, with Dync1h1 mutation. Dynactin
heavy (DCTN1) and light (DCTN3) subunits were studied in
the CNS of humans with sporadic ALS (SALS), mice with
hSOD1G93A (SOD1/?), Dync1h1 (Cra1/?), and double
(Cra1/SOD1) mutation at presymptomatic and symptomatic
stages. In SALS subjects, in contrast to control cases,
expression of DCTN1-mRNA but not DCTN3-mRNA in the
motor cortex was higher than in the sensory cortex. However,
the mean levels of DCTN1-mRNA and protein were lower in
both SALS cortexes and in the spinal cord than in control
structures. DCTN3 was unchanged in brain cortexes but
decreased in the spinal cord on both mRNA and protein
levels. In all SALS tissues immunohistochemical analyses
revealed degeneration and loss of neuronal cells, and poor
expression of dynactin subunits. In SOD1/? mice both
subunits expression was significantly lower in the frontal
cortex, spinal cord and hippocampus than in wild-type
controls, especially at presymptomatic stage. Fewer changes
occurred in Cra1/SOD1 and Cra1/? mice.It can be con-
cluded that in sporadic and SOD1-related ALS the impair-
ment of axonal retrograde transport may be due to dynactin
subunits deficiency and subsequent disturbances of the
whole dynein/dynactin complex structure and function. The
Dync1h1 mutation itself has slight negative effect on dyn-
actin expression and it alleviates the changes caused by
SOD1G93A mutation.
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ALS Amyotrophic lateral sclerosis
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FTD Frontotemporal dementia
FTLD Frontotemporal lobar degeneration
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MND Motor neuron degeneration
CNS Central nervous system
DCTN1 Dynactin heavy chain
DCTN3 Dynactin light chain
hSOD1 Human copper–zinc superoxide dismutase 1
Dync1h1 Cytoplasmic dynein 1 heavy chains
Cra1 Cramping 1
KIF Kinesin
PBP Progressive bulbar palsy
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Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most
devastating, incurable neurodegenerative disease charac-
terized by a progressive and selective loss of motor neurons
[1]. Being the 4th most frequent neurodegenerative disease
(after AD, FTD and PD), ALS is responsible for 1 for every
1,000 deaths worldwide [2]. About 85 % of ALS cases are
sporadic ALS (SALS) and the remaining 15 % familial
(FALS). Mutations in SOD1 gene are responsible for 20 %
of FALS and up to 7 % of SALS cases [3, 4]. Despite a
large number of studies, pathogenesis of motor neurons
degeneration in ALS is still unclear. Beside the genetic
factors, the potential diseases causes include excitotoxicity,
deprivation of neurotrophic factors, defects of RNA pro-
cessing, environmental toxins, oxidative stress and defects
in axonal transport along microtubules [5–7]. The latter is
crucial for normal function of motor neurons, highly spe-
cialized cells with very long axons. The major components
of axonal transport are motor proteins, kinesins and dynein/
dynactin complexes that move cargo along microtubules
[8–10]. Transgenic mice that express human SOD1 gene
with G93A mutation develop ALS-like symptoms and are
used as a classic model for the disease studies [11–13].
Also the Cra1 mice, with point mutations in the cytoplas-
mic dynein 1 heavy chain (Dync1h1), demonstrate symp-
toms of motor neuron degeneration and impaired dynein/
dynactin mediated retrograde transport [14, 15]. Cyto-
plasmic dynein is a huge, multi-subunit protein complexes.
Its heavy chains show ATPase activity, interact with
intermediate and light chains to form the cargo-binding
complex and bind the whole complex to microtubules [16,
17]. For its full functional activity dynein requires dynac-
tin, another large, multi-protein complex [18, 19]. The
largest dynactin subunit (DCTN1 or p150Glued) encoded by
DCTN1 gene binds directly to dynein and microtubules
what allows dynein to traverse the microtubule net over
long distances. A mutation in the p150 subunit was linked
to ALS with vocal cord paresis in humans [20]. The
smallest dynactin subunit (DCTN3 or p24) encoded by
DCTN3 gene is probably involved in protein–protein
interactions and thus participate in assembly of the dyn-
actin complex [21]. Defects in the function of dynein/
dynactin complex are causally linked to multiple neuro-
degenerative diseases but their molecular mechanism is not
clear [22–24]. Previously we indicated affected expression
of N-kinesins (involved in the anterograde transport) and
C-kinesin (participating in the retrograde transport) in the
CNS of sporadically and genetically determined motor
neuron degeneration in humans and transgenic mice [25,
26]. In the present work we focused on dynein–dynactin
mediated transport studying dynactin heavy (DCTN1) and
light (DCTN3) subunits mRNA and protein expression and
localization in the motor and sensory brain cortex, hippo-
campus and spinal cord obtained from autopsy of SALS
human subjects, and Dctn1 and Dctn3 mRNA expression in
mice with human SOD1G93A (SOD1/?), Dync1h1 (Cra1/
?) and double mutation (Cra1/SOD1) at the presymp-
tomatic and symptomatic stages.
Experimental Procedure
Human Tissues
The human material included samples of motor and sensory
brain cortex, and cervical spinal cord. The tissues were
obtained from autopsy of five SALS and five control sub-
jects with no neurodegenerative disease (Table 1). Autop-
sies were performed within 72 h from death. The SALS
patients were diagnosed at the Department of Neurology,
Medical University of Warsaw. They fulfilled the El
Escorial criteria for ALS and died in the course of clinically
and morphologically definite sporadic ALS. The disease
duration ranged from 4 months to 9 years (Table 1).
RT-qPCR
Total RNA isolated by Chomczynski and Sacchi method
[27] was reverse transcribed to a single-stranded cDNA
according to the manufacturer’s protocol (Invitrogen,
USA). Quantitative gene expression assay was performed
using TaqMan probes on the StepOnePlus apparatus
(Applied Biosystems), as indicated earlier (Kuz´ma-Ko-
zakiewicz et al., 2012). Expression of DCTN1 and DCTN3
was normalized against the housekeeping genes (B2 M and
GusB) (Table 2). Measurements of mRNA expression were
based on four independent reactions for each cDNA sam-
ple. The 120 ng and 480 ng of cDNA were used in
duplicates. The results were calculated with normalization
of Ct values to the mean Ct value for the reference genes.
The relative changes in genes expression were analyzed
using the DCt method. Statistical analysis was performed
using GraphPad Prism (GraphPad Software, San Diego,
CA, USA). Results were expressed as mean ± SEM and
the data were analyzed by Student’s and Mann–Whitney U
tests. Means were considered statistically significant at
p \ 0.05.
Western Blotting
Samples of freshly frozen human tissues were homoge-
nized in isotonic PBS, centrifuged (20 min, 12,0009g,
4 C), and the obtained supernatant was used for further
studies. Western blotting was performed after electropho-
resis in polyacrylamide gel according to Laemmli [28],
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with rabbit polyclonal DCTN1 (H-300) antibodies (Santa
Cruz Biotech; 135–150 kDa) and goat polyclonal DCTN3
antibodies (Abcam; 20–21 kDa). Mouse monoclonal anti-
beta-actin antibody (Sigma) was used as control. Blots
were visualized using Pierce ECL Western Blotting
Substrate (Thermo Sci.). System UVI-KS4000 (Syngen
Biotech.) was used for densitometric analysis of the results.
Immunohistochemical Study
Formalin-fixed and paraffin-embedded tissue samples from
the primary motor cortex (precentral gyrus), primary sensory
cortex (postcental gyrus) and spinal cord of both SALS and
control cases were used. The immunohistochemical reac-
tions with primary antibodies against DCTN1 (1:100; Santa
Cruz Biotech.) and DCTN3 (1:500; Atlas) were performed
according to streptavidin–biotin peroxidase method. A rou-
tine microwave pretreatment of antigen retrieval (boiling in
10 mM citrate buffer, pH 6.0) was performed before incu-
bation (1 h, room temperature) with the primary antibodies
against DCTN3. Afterwards the sections were incubated
with the secondary antibodies (Rabbit ABC Staining System,
Santa Cruz Biotech.) followed by 3,30-diaminobenzidine.
The examined material was evaluated at light microscopy
(Nikon) and the numerical aperture of the lens was 40.
Mouse Tissues
The studies were conducted on mouse strain C57BL/6GJ-
C3H/HeJ (B6-C3H) hybrids with human SOD1G93A
mutation (SOD1/?), with dynein heavy chain 1 mutation
(Dync1h1; so-called Cra1/?), with double Dync1h/
SOD1G93A mutation (Cra1/SOD1), and genetic back-
ground- and age-matched wild-type controls (?/?). The
hSOD1G93A males (B6 background; Jackson Laborato-
ries, Barr Harbor, ME, USA) were crossed with Cra1/
? heterozygote females (C3He background; Ingenium
Pharmaceuticals AG, Martinsried, Germany) [29]. There
were 6 males in each animal group. Mice were at the
presymptomatic stage without symptoms of neurodegen-
eration and at the symptomatic end stage. The presymp-
tomatic SOD1/? and Cra1/SOD1mice were 70 days old,
while the Cra1/? mice—70 and 140 days old. The symp-
tomatic SOD1/? and Cra1/SOD1mice were 140 days old
and Cra1/? mice—365 days old.
RT-PCR
The expression of dynactin heavy (Dctn1) and light sub-
units (Dctn3)-mRNA was studied in mouse brain frontal
cortex, cervical spinal cord and hippocampus included as a
control structure. Total RNA was isolated with the use of
NucleoSpin RNAII kit (Macherey–Nagel) according to
manufacturer’s protocol followed by reverse transcription,
polymerase chain reaction and DNA electrophoresis in
agarose gel. Specific oligonucleotide primers for mouse
dynactin Dctn1 were: 50-TGCTGCTCCAGGAGAGGTGA
and 50-CCTAAGAAGGCACCGACAGC, and for dynactin
light chain (Dctn3) were as follows: 50-GGCCTCGAAG
TTGCAGTTCA and 50-CTCTGCTGGCTTCACTTGCT.
The primers for ribosomal S12 protein RNA band (Rps12,
housekeeping gene, internal control) were: 50-TCGCAT
CCAACTGTGATGAG and 50-TCTTTGCCATAGTCCT
TAACCACTACG. RNA level was measured in semi-
quantitative way and expressed as the ratio of the optical
density band of studied dynactin to the optical density of
ribosomal S12 protein RNA. Each assay was performed in
duplicates and repeated two times. System UVI-KS4000
(Syngen Biotechnology) was used for densitometric ana-
lysis. Results were expressed as mean ± SD and the data
were analyzed by the two-way analysis of variance
Table 1 Clinical profiles of SALS patients and control subjects
Cases with SALS Control cases
No Sex Age, years Disease duration Type of SALS No Sex Age, years Cause of death
1 F 76 9 years Classic A F 87 Heart infarction
2 F 76 3 years Classic B F 63 Acute lymphatic leukemia
3 F 58 2 years Classic C M 61 Acute heart failure
4 M 48 4 months PBPa D M 49 Acute myeloid leukemia
5 M 63 6 months Classic E F 63 Heart infarction
a Progresive Bulbar Palcy
Table 2 TaqMan probes used in the studies
Gene
Symbol




GusB Glucuronidase, beta NM_010368 Hs99999908_m1
DCTN1 Dynactin 1 NM_001135040 Hs00896387_m1
DCTN3 Dynactin 3 NM_007234 Hs00989657_m1
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(ANOVA). Quantitative comparison between studied
groups was performed by Student’s t test using Statistica
9.0 (StatSoft Inc, USA). Means were considered statisti-
cally significant at p \ 0.05.
Ethics Statement
The studies on human tissues were approved by the
Bioethic Committee at the Medical University of Warsaw,
Poland (KB/253/2003) in accordance with Declaration of
Helsinki. Non of the patients (while still alive) or their
relatives (after the patient’s death) disagreed on the autopsy
and tissue studies. The studies on mice tissues were
approved by the Ethic Committee for Experiments on
Animals at the Medical University of Warsaw, Poland (no
AO-KEZ/622/3).
Results
Dynactin in Human CNS
Expression of DCTN1-mRNA in the motor cortex of indi-
vidual SALS brains was higher than in the corresponding
SALS sensory cortex (Fig. 1). The mean DCTN1-mRNA
expression was slightly higher in SALS motor than SALS
sensory cortex (Table 3). However, in SALS brains
expression of DCTN1 in both types of cortex and also in the
spinal cord, was lower than in control tissues (Table 3).
The DCTN3-mRNA expression in the motor and sen-
sory cortex of individual SALS cases was at the same level
(Fig. 1). The mean expression of DCTN3-mRNA was
similar in SALS motor and SALS sensory cortex but
slightly lower than in control cortexes. It was also lower in
SALS spinal cord compared to the control tissue (Table 3).
All changes were statistically not significant.
In SALS motor cortex the level of DCTN1 protein was
lower than in SALS sensory cortex, and lower than in
corresponding control cortexes (Fig. 2). It was also lower
in SALS spinal cord than in the control tissue (Fig. 2). The
level of DCTN3 protein was similar in both parts of brain
cortex, and there were no differences between SALS and
control cases (Fig. 2). In the spinal cords, the level of
DCTN3 protein was much lower in SALS than in the
control tissues (Fig. 2).
Morphological examination revealed degeneration and
loss of neurons in SALS—severe in the anterior horns of
the spinal cord and mild in the motor cortex while the
Fig. 1 Expression of dynactin
DCTN1 and DCTN3 mRNA in
the CNS of SALS and control
cases. The expression was
studied by real-time qPCR, as
described in the Material and
method section. The results
were quantified as the ratio of
studied dynactin (DCTN1 or
DCTN3) expression to the
expression of housekeeping
genes (B2M and GusB; DCt
method). No. 1–5, cases with
SALS; a–e, control cases. Black
bars motor cortex; striped bars
sensory cortex
Table 3 Mean dynactin subunits expression in various parts of
human CNS
Part of CNS Cases DCTN1 DCTN3
Motor cortex Control 0.104 ± 0.049 0.240 ± 0.038
SALS 0.052 ± 0.019 0.171 ± 0.013
Sensory cortex Control 0.162 ± 0.096 0.184 ± 0.028
SALS 0.031 ± 0.003 0.153 ± 0.025
Spinal cord Control 0.093 ± 0.049 0.115 ± 0.028
SALS 0.045 ± 0.006 0.056 ± 0.005
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sensory cortex was relatively intact. In immunohisto-
chemistry DNCT1 protein was seen in pericaria, axons, and
dendrites of neurons, and was less intense in SALS than in
the control material (Fig. 3a–f). The difference in DNCT1
expression was especially evident in the anterior horns of
individuals with SALS (Fig. 3c, f) where the majority of
preserved motoneurons revealed mild immunoreactivity in
cell bodies and weak or sometimes even absent immuno-
reactivity in neuronal processes. Immunoexpression of
DNCT3 in SALS was poor in all examined cases and in all
CNS structures. In the motor and sensory cortex only single
neurons demonstrated weak immunolabel of cell pericarion
while in the control material the immunoreactivity was
much stronger and visible mainly in neuronal processes
(Fig. 4a–e). The same phenomenon was observed in the
anterior horn motoneurons (Fig. 4c, f).
Dynactin in Transgenic Mice CNS
In SOD1/?, but neither in Cra1/SOD1 nor Cra1/? mice, the
expression of dynactin subunits Dctn1- and Dctn3-mRNA
was significantly decreased in all studied parts of the CNS
compared to the age-matched wild type controls (Fig. 5;
Table 4). In the frontal brain cortex of SOD1/? mice the
expression of each subunit was lower at the presymptomatic
(age 70 days) than at the symptomatic stage (age 140 days).
When compared to the control tissues, Dctn1 expression was
decreased to about 65 % (p \ 0.0001) and 80 %
(p \ 0.005) in presymptomatic and symptomatic mice,
respectively, and that of Dctn3 to 55 % (p \ 0.0001) and
70 % (p \ 0.001), respectively (Table 4). In Cra1/SOD1
hybrids the expression of Dctn1-mRNA was slightly but not
significantly increased compared to the control groups,
whereas that of Dcnt3 was decreased to 55 % (p \ 0.0001)
and 80 % (p \ 0.005) at the presymptomatic and the
symptomatic stage, respectively (Table 4; Fig. 5). In Cra1/
? mice the expression of Dctn1-mRNA was slightly but
significantly lower at both stages (age 70 days, p \ 0.01,
age 356 days, p \ 0.0.01), whereas that of Dctn3 was
practically unchanged (Fig. 5).
In the spinal cord of SOD1/? mice the expression of
both dynactin subunits was lower at the presymptomatic
stage (p \ 0.001 for each subunit) than at the symptomatic
stage (p \ 0.0001 for Dctn1 and p \ 0.001 for Dctn3)
(Table 4). In Cra1/SOD1 mice the dynactins expression
was slightly decreased when compared to the control ani-
mals but the changes were not significant (Fig. 5). How-
ever, when compared to SOD1/? mice, the expression of
Dctn1 was significantly higher at the presymptomatic stage
(p \ 0.005), and that of Dctn3 was higher in both stages
(p \ 0.0005 and p \ 0.0001, respectively). In all Cra1/
? mice Dctn1-mRNA was unchanged and Dctn3 signifi-
cantly lower than in control group only at the presymp-
tomatic stages (age 70 and 140, p \ 0.001) (Table 4,
Fig. 5).
In the hippocampus of SOD1/? mice expression of each
subunit was slightly but significantly lowered at both stages
(p \ 0.0005 and p \ 0.01 for Dctn1, p \ 0.0001 and 0.001
for Dctn3, at the presymptomatic and symptomatic stage,
respectively). In Cra1/SOD1 and Cra1/? mice expression
of both dynactin subunits was unchanged (Fig. 5).
Analysis of variance showed that Dctn1-mRNA and
Dctn3-mRNA expression was dependent on both the
mutation and the clinical stage only in the frontal cortex
[F(3.86) = 2.98, p = 0.036; F(3.87) = 6.91, p = 0.0003,
respectively].
Fig. 2 Expression of dynactin DCTN1 and DCTN3 protein in the
CNS of SALS and control cases. The expression was studied by
Western blotting, as indicated in the Material and method section.
Comparable amounts of protein (20 lg for DCTN1 and 40 lg for
DCTN3) from representative control (no D) and SALS (no 4) brains
were run in each lane. A; DCTN1: line 1 control motor cortex (optical
density: OD 651), line 2 control sensory cortex (OD 847), line 3
SALS motor cortex (OD 439), line 4 SALS sensory cortex (OD 519),
line 5 control spinal cord (OD 940), line 6 SALS spinal cord (OD
627). b DCTN3: line 1 control motor cortex (OD 211), line 2 control
sensory cortex (OD 238), line 3 SALS motor cortex (OD 210), line 4
SALS sensory cortex (OD 290), line 5 control spinal cord (OD 180),
line 6 SALS spinal cord (OD 92)
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Discussion
Dynein/dynactin complex is involved in axon maintenance,
removal of damaged organelles, vesicles, misfolded and
aggregated proteins from axons to the cell body [30]. Many
point mutations in the gene encoding for dynactin were
found in sporadic and familial cases of ALS [31, 32]. The
largest dynactin subunit (DCTN1, called also p150Glued)
which mediates dynein–dynactin interaction is a critical
component of the whole dynein/dynactin complex. It was
found that a single base-pair change leading to a glycine-
59-serine (p.G59S) substitution in glycine-rich domain of
this subunit accelerated motor neuron degeneration in
humans and mice which resembled ALS [33, 34]. Vilarino-
Guell et al. [35] after sequencing all DCTN1 exons and
exon–intron boundaries in 286 samples diagnosed with
neurodegenerative diseases (PD, FTLD, ALS) concluded
that pathogenic mutations in DCTN1 are rare. Lately Fu-
jiwara and Morimoto [7] discovered that overexpression of
p150Glued and microtubule stabilization cooperatively
suppress axon degeneration.
In the present study we found that in individual SALS
subjects, DCTN1-mRNA expression was higher in the
motor than in the sensory brain cortex. In our earlier
Fig. 3 Representative immunohistochemistry for dynactin DCTN1
on sections from SALS and control human cases. a Immunopossitive
neurons and their processes in SALS motor cortex and visible
moderate loss of neuronal cells; b positive immunoreactivity in SALS
neurons and axons in the sensory cortex; c moderate immunoexpres-
sion in pericaria and axons of the preserved SALS anterior horn
motoneurons with features of degeneration; d pronounced immuno-
reactivity of control neuronal processes and pericaria in the motor
cortex; e positive immune reaction of different intensity in control
axons and neuronal pericaria in the sensory cortex; f very strong
immunoreactivity of processes and motoneuron pericaria in control
spinal cord anterior horn. Bars 100 lm each
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studies conducted on the same SALS subjects, we found
that kinesins-mRNA expression was also higher in the
motor cortex [25]. In the control brain cortexes (without
neurodegenerative disorders), the situation was opposite—
DCTN1 and kinesins-mRNA expression was lower in the
motor compared to the sensory cortex. However, the
increase of DCTN1-mRNA in SALS was not followed by
the increase of protein, the level of which in the motor
cortex was even lower than in the sensory cortex. This may
indicate that in the motor cortex, the structure usually
affected by the process of degeneration, the effort is made
to restore bidirectional axonal transport but it is not suffi-
cient since mRNA is not effectively translated to protein.
The highest increase of DCTN1-mRNA and also kinesins-
mRNA expression was observed in the subjects with short
disease duration (4 months, 2 years). However, the low
number of studied brains, due to difficulties obtaining
human tissues, makes it impossible to find the correlation
between the disease duration and motor proteins
expression.
The comparison of SALS and control cases indicated
lower values of DCTN1 expression (on the mRNA and
protein level) in both SALS cortexes and also in the spinal
cord. Those results were supported by immunoexpression,
which indicated that DCTN1 protein in the preserved
SALS motoneurons revealed mild immunoreactivity and
Fig. 4 Representative immunohistochemistry for dynactin DCTN3
on sections from SALS and control human cases. a Weakly
immunopositive single neuron in SALS motor cortex (arrow) and
visible loss of neurons; b mostly negative immune reaction in SALS
neurons and axons (arrow) in the sensory cortex; c very poor or
absent immunoexpression in the preserved motoneurons with features
of degeneration in the anterior horn of SALS spinal cord; d weak
immunolabel in pericaria of neurons and pronounced in their
processes in the control motor cortex; e strong immunoreactivity of
axons and poor of neuronal pericaria in the control sensory cortex;
f weak immunoexpression in control pericaria of anterior horn
motoneurons and mild in axons (arrows). Bars 100 lm
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was less intense than in control material—the difference
was especially evident in the spinal cord anterior horns.
Our results are with agreement with the studies of Ikenaka
et al. [36], who observed the reduction of dynactin 1
expression in spinal motor neurons of ALS patients and
indicated its connection with the impairment of auto-
phagosomes, a cargo of dynien/dynactin complexes.
Differently to DCTN1, in the brain cortex of SALS
cases the expression of DCTN3 was similar in both SALS
cortexes and it didn’t differ from the expression in control
cortexes (on both mRNA and protein levels). In the spinal
cord the expression of DCTN3 was much lower in SALS
than in control tissues. In immunohistochemistry DCTN3
was hardly seen in all SALS tissues but was much better
visible in controls.
Mutations in the gene encoding SOD1 cause 2–3 % of all
ALS cases and induce motor neuron degeneration in
transgenic mice [3, 23]. Mutant SOD1 affects bidirectional
axonal transport of specific cargoes but the precise mech-
anism is not fully understood [23]. According to Ligon et al.
[37] mutant SOD1 associates with dynein, alteres its cel-
lular localization and consequently the function of dynein/
dynactin complex. Zhang et al. [38], indicated that mutant
but not normal SOD1 directly interacts with dynein heavy
chain forming aggregates. We observed a significant
decrease of dynactin heavy and light subunits (Dctn1,
Fig. 5 Expression of dynactin
Dctn1 or Dctn3 mRNA in the
CNS of transgenic mice. The
expression was determined by
RT-PCR and expressed as the
ratio of the optical density (OD)
value of Dctn1 or Dctn3 to the
optical density of S12 protein
RNA, as indicated in the
Material and Method section.
Filled diamond dashed lines
wild-type controls (?/?); filled
triangles Cra1/? mice; filled
circles SOD1/? mice; filled
squares Cra1/SOD1 hybrides
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Dctn3) expression in mice with human SOD1G93A muta-
tion. Differently than in human SALS cases, where only
DCTN1 expression was decreased, in mice the expression
of both dynactin subunits was decreased in the frontal brain
cortex comparing to wild-type controls. Similar to humans,
the expression of studied dynactins was decreased also in
the spinal cord. As we showed earlier the expression of
kinesins KIF5A and KIF5C involved in the anterograde
transport but also the expression of KIFC3 participating in
the retrograde transport, was significantly increased in the
frontal cortex and the spinal cord of SOD1/? mice com-
paring to the corresponding control tissues [25]. Interest-
ingly the changes in dynactin subunits preceded those in
kinesins, since the decrease of dynactin subunits expression
was observed already at the presymptomatic stage and was
more severe than at the symptomatic stage, whereas that of
kinesins (including KIFC3) appeared later, at the symp-
tomatic stage. Such differences indicate the existence of a
compensatory mechanism aiming to restore affected bidi-
rectional axonal transport. All the more, that dynactin has
been implicated not only in the retrograde but also in the
anterograde transport, and its large subunit have been
shown to interact with particular kinesins [10, 39, 40].
All motor proteins transport their cargoes on tracts formed
by microtubules. Microtubules assembly, stabilization and
organization into bundles depend on tau protein [41]. Tau also
enhances the attachment of dynein/dynactin complex to
microtubules by binding the N-terminal domain to the C-ter-
minus of dynactin p150 (Dctn1) subunit [42]. As we have
previously shown, tau expression is lower in mice with SOD1
mediated ALS than in wild-type animals due to defective
N-terminal alternative splicing [43, 44]. It indicates that
dynein/dynactin-dependent transport may be impeded due to
tau dysfunction but also, as we have just shown, by significant
decrease of dynactin Dctn1 and Dctn3 subunits expression.
Cra1 mice with dynein heavy chain (Dync1h1) mutations
present phenotype similar but milder than SOD1G93A mice
but in contrast to SOD1 mice their life span remains almost
unchanged [14, 15, 45]. However, the involvement of the
Dync1h1 mutations in pathogenesis of motor neuron
degeneration is controversial [46, 47]. According to Dupuis
et al. [48], Cra1 heterozygotes do not display typical feature
of motor neuron disease, even in aged animals, but instead
they develop an early-onset sensory neuropathy. We found
much fewer changes in the expression of motor proteins in
the CNS of Cra1/? than SOD1/? mice. In Cra1/? mice we
observed a slight decrease of Dctn1-mRNA only in the
frontal cortex, and decrease of Dctn3-mRNA only in the
spinal cord. Kinesin KIFC3-mRNA expression (involved in
retrograde transport) was unchanged in Cra1/? mice, but
that of N-kinesins (anterograde transport) was raised,
especially at the symptomatic stage [26]. There were also
clear differences between tau expression and its alternative
splicing in mice with Dync1h1 and SOD1G93A mutation
[44]. All those results indicate that the axonal transport may
be affected in Cra1/? mice due to dysfunction of the axonal
motors and the structure of cytoskeleton but not as severely
as in SOD1/? mice.
In mice with double SOD1G93A and Dync1h1 muta-
tions defective retrograde transport is partially corrected
and the life span of SOD1 mice extended [45]. According
to Fergani et al. [49] increased survival of double hetero-
zygotes may be mediated by a reversal in energy deficit and
increased IGF-1 availability. The Dync1h1 mutation also
attenuates motor neuron degeneration in SOD1G93A mice
[29]. Zhang et al. [38] suggested that mutant SOD1 shows
very low affinity for mutant dynein (in Cra1 and Loa mice)
and thus the protein aggregation and SOD1 toxicity in
double transgenic animals may be reduced. Although the
underlying mechanisms of its protection are not clear, we
observed fewer changes in the expression of both dynactin
subunits, and also kinesins in the CNS of Cra1/SOD1 mice
comparing to SOD1/? , and more changes comparing to
Cra1/? transgenics [26]. In the spinal cord of Cra1/SOD1
Table 4 Percentage of dynactin subunits expression in the CNS of transgenic mice
Dctn1 Dctn3
Part of CNS Clin. stage SOD1/? Cra1/SOD1 Cra1/? SOD1/? Cra1/SOD1 Cra1/?
Remaining expression, %
Frontal cortex Presympt. 65* 110 80* 55* 55* 90
Sympt. 80* 110 85* 70* 80* 90
Spinal cord Presympt. 65* 80 95 60* 80 70*
Sympt. 75* 80 100 70* 95 90
Hippoc. Presympt. 85* 100 105 80* 95 105
Sympt. 85* 110 100 90* 110 110
All presymptomatic mice were at the age of 70 days, symptomatic SOD1/? and Cra1/SOD1 at the age of 140 days, and symptomatic Cra1/? at
the age of 365 days. The values were calculated in comparison with the age-matched wild-type control mice, taken as 100 %
* Data statistically significant when calculated for the expression level
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presymptomatic mice both dynactins expression was sig-
nificantly higher than in SOD1/? mice and that of Dctn3
was higher also at the symptomatic stage. In concordance
with other authors [29, 45, 49] our results confirm that the
double Cra1/SOD1 mutations protects axonal transport
which in the spinal cord seems to be relatively normal. It
may be worth noticing that in the hippocampus, the
structure included into our studies as a control one, a slight
decrease of both dynectin subunits expression was
observed in SOD1/? mice, whereas there were no changes
either in Cra1/? or in Cra1/SOD1 transgenics.
It can be concluded that in SALS and SOD1-related
ALS the impairment of dynein-mediated retrograde axonal
transport and degeneration of motor neurons may be rela-
ted to dynactin subunits deficiency and subsequent dis-
ruption of the whole dynein/dynactin complex structure
and function. The Dync1h1 mutation itself has slight neg-
ative effect on dynactin subunits expression but positively
affects the changes caused by SOD1G93A mutation.
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